

PUBLIC OPINION RESEARCH INTO BIOTECHNOLOGY ISSUES

2000701 BJ Ware 2 15g W2 Is.

SECOND WAVE

Presented to the Biotechnology Assistant Deputy Minister Coordinating Committee (BACC), Government of Canada

July 2000

Earnscliffe RESEARCH & COMMUNICATIONS 46 Elgin Street, Suite 200, Ottawa, Ontario, Canada K1P 5K6



Prepared for the Biotechnology Assistant Deputy Minister Coordinating Committee, Government of Canada, by Pollara Research and Earnscliffe Research and Communications.

The opinions and statements in this publication do not necessarily reflect the policy of the Government of Canada.

TABLE OF CONTENTS

SECTION

POLLARA AND EARNSCLIFFE

PAGE NUMBER

А.	INTRODUCTION	4
В.	EXECUTIVE SUMMARY	6
C.	THE SURVEY – DETAILED FINDINGS	.10
	Awareness, Familiarity and Interest Levels Assessments of Benefits and Drawbacks	.10
	The Question of Risk	. 10
	The Role of Government	
	Decision Making in Biotechnology	.32
	Argumentation	.35
	GM Food	.40
D.	THE FOCUS GROUPS – MAIN FINDINGS	.44
Е.	CONCLUSIONS	.50
F.	APPENDIX	. 52
	Moderator's Guide	.53
	Questionnaire	.59



A. INTRODUCTION

Pollara Research and Earnscliffe Research and Communications are pleased to present this report on a public opinion research program conducted in late January and early February 2000 for the Biotechnology Assistant Deputy Minister Coordinating Committee, Government of Canada. The research was comprised of two separate instruments: a telephone survey and a set of focus groups. This report presents the findings of both.

The research was designed to establish whether there had been significant changes in public opinion towards biotechnology since the previous research phase in the fall of 1999.

Using some elements from the benchmark survey questionnaire from the fall of 1999, Earnscliffe designed and conducted a national telephone survey of 1000 people between January 31 and February 4, 2000. That was followed up with focus groups in the third week of February, using much of the focus group agenda from the fall as well.

The research probed four areas of investigation in order to track current opinion on biotechnology and compare the results with the fall survey. The areas included:

- overall awareness and familiarity;
- perceived risks, benefits and drawbacks;
- assessments of government performance in biotechnology, preferred roles for government and future priorities; and
- the acceptability of various products and processes.

The final results report on the views of a random sample of 1000 Canadians and carry a margin of error for the national sample of +/-3.0%, nineteen times out of twenty. Margins of error for sub-samples range up to +/-3.9% for smaller regional samples. Precise margins of error can be provided for the variety of aggregated sub-samples.

4



Three nights of focus groups (six groups in all) were conducted in Montreal, Toronto and Vancouver between February 9, and February 10, 2000. The research followed a consistent agenda for discussion and was designed to probe in more detail opinion underlying the results of the telephone survey. Each night of the focus group wave comprised a group of approximately ten participants drawn from the general population and a group of similar size of *Involved Canadians*, our proprietary population segmentation of Canadians who are significantly more interested and involved in public policy issues.

This report is divided into two main sections: results of the survey, followed by a summary of the learnings from the focus groups.

For ease of communications, further information can be obtained from Earnscliffe Research and Communications. Please contact either of the following at our offices, (613) 233-8080, or via e-mail:

Elly Alboim Jeff Walker elly@earnscliffe.ca jwalker@earnscliffe.ca

B. EXECUTIVE SUMMARY

Overall the survey indicates that awareness of biotechnology is growing, though that is having no real impact on self-reported familiarity and interest. As a result, the depth of knowledge of the field remains relatively low. Nevertheless, growing awareness is translating into increased levels of concern on all fronts, particularly health. It also appears to be fuelling somewhat more interest in the ideas of more regulation and more research into the impacts of biotech applications. Federal government performance ratings are consistent with these growing concerns, eroding somewhat on all indicators. However, the generalized presumption among Canadians that their food is safe appears to be relatively insulated from these trends.

The message from this updated survey is a bit mixed. On the one hand, these results do not signal a major absolute shift in opinion despite months of intense media coverage and debate. Most Canadians remain disengaged and disinterested and there has been no galvanizing or catalytic event to change that.

On the other hand, the public opinion numbers continue to move in a consistent direction, towards higher overall concern. Though the movement is *comparatively* small, it is quite marked given the relatively short space of time between surveys. Significantly as well, the movement is larger among *Involved Canadians*, that 30% segment of the population that Earnscliffe has identified as more activist in its behaviour and more influential than other cohorts. If the current pace and direction of change continues, the result over time might be an undermining of confidence in the biotechnology sector and in the federal government's ability to address the issues that biotech raises.

The highlights of the findings include:

Awareness of biotechnology-related issues has risen substantially. There has been a 15% increase in the number of Canadians who say they have heard something about biotech in the past three months, now 53%.

Familiarity and interest in biotech have not grown significantly. The number of those who say they are very or somewhat familiar with biotechnology has grown by three percentage points since October, though only 6% are very familiar now. Interest levels – quite low -- are unchanged since October.

There has been a downward trend in the assessment of benefits vs. drawbacks, especially in health and food.

Since October, 13% fewer people believe that there are major or modest benefits to health from biotechnology. The number is almost precisely the same (12%) when it comes to benefits in the quality of food, while those perceiving drawbacks in those areas have gone up 8% and 9%, respectively.

Assessments of federal government performance are down slightly in all areas. While there is no change in *excellent* and *good* overall performance ratings, they still hover under 20%. However, *poor* overall performance ratings have risen from 26% to 29%, with *health* performance down five percentage points (22% say good or excellent) and *ensuring interests of Canadians taken into account* down 4% (14% say good or excellent).

The desired priority list for government remains largely unchanged from October. Health, environment, the ethical use of biotech and informing Canadians are the main issues, while economic benefits are waning as a priority.

Health remains the most effective benefits case for communications messaging. The same percentage as last time see it as the strongest argument (36%). Biotechnology's potential to help solve world hunger is the second strongest argument (29%), increasing by 4% since October.

Long-term risk is by far the most effective negative argument. In fact, 5% more see it as the strongest negative argument (now 44%).

Experts and science remain the preferred decision-making drivers. There was no change in how most people wanted decisions made: they continue to believe that experts should be more influential than members of the public and they want science to trump ethics when the two come into conflict.

- 59% would rather rely on experts over the public
- Two-thirds would rather rely on science over ethics

7

The demand for regulation and caution is growing. For instance, 7% more *disagree* with the proposition that "government should encourage biotech although there may be unknown risks" (37% now disagree.) Other results in this area include:

POLLARA AND EARNSCLIFFE

- A 4% increase in agreement with the idea of "government regulating biotech more than other sectors" (73% now agree)
- A 4% increase in agreement with the idea of "conducting further research into long-term health and environmental impacts before allowing any further use of biotech" (87% now agree)
- A 5% increase in agreement with the idea of "slowing use of biotechnology until more is known" (72% now agree)
- 10% more *disagree* with the idea that "enough is known about safety of products made through biotechnology to allow them to be used" (54% now disagree)

The presumption of the safety of food remains insulated from growing concerns overall. Though within the margin of error, there has been a 2% increase in the assumption that food on store shelves is safe (now 71%), with a similar increase of 4% in the assumption that food has been tested for safety by government (now 77%.) At the very least, given the margin of error, there has been no substantial deterioration in this assessment despite the intensified debate about GM foods.

The focus groups were consistent with the telephone survey. Participants were somewhat more aware of biotechnology and its applications than they had been in the fall but were no more engaged, interested or knowledgeable. Consistent with previous focus group findings, few are prepared to fully endorse or fully oppose biotechnology writ large. Instead, most Canadians make distinctions between biotech applications that are acceptable and not acceptable. Health and medical applications are consistently met with positive sentiment. GM food applications continue to be met with resistance by most, although this resistance has yet to catalyze determined behaviour to oppose the production of these foods or to avoid eating them. The safety of food continues to be an issue most people separate from their concerns about GM food, as most Canadians believe the food they purchase is safe and is tested for safety. In addition, these results indicate that few have any sense of what the federal government is doing in this field and confidence is eroding about the federal government's ability to address key issues (particularly in terms of health and environmental risks) that biotech raises.

A final word about the demand for information about biotechnology. Though the survey did not ask the full battery of questions posed in October, it did probe respondents' views about the role of government in providing information. An overwhelming number of people wanted government to provide them with information and then let them decide for themselves whether to use biotechnology products. In focus groups, most people advocated an "informed choice" approach to GM foods, leading them to support some form of labelling. Many said they would accept a voluntary process but indicated they would expect a mandatory solution if the voluntary process did not produce results.



Awareness, Familiarity and Interest Levels

POLLARA AND EARNSCLIFFE

Once again, the survey tested top-of-mind reactions to biotechnology in the way it had in the fall survey – asking three consecutive questions about *biology*, *technology* and *biotechnology*. Again, there are far more positive associations with *technology*, an even split between positive reaction and neutrality towards *biology* and a decidedly neutral tilt towards *biotechnology*. However, despite the differences the words create, entrenched negative opinion towards biotechnology is still quite low and has not changed at all between surveys.

Focus groups revealed that public opinion towards high technology continues to evolve in Canada, as more and more people invest their hope for the future success of the Canadian economy in high technology. Correspondingly, the concept has become much less threatening, no longer automatically conveying job loss and plant closures. There is a bit of a positive "halo" that the word *technology* casts over any phrase or description that uses it.



As further evidence of the positive halo generated for most people, a strong majority of Canadians still want Canada to lead the world in the development of biotechnology. That number has dropped somewhat from October but is still quite significant.

]	The second s	ke to see Canada lea development of biot		
ebruary	23	44	22	7 4
October	24	48	19	4 4

11

In examining those who expressed negative reactions to biotechnology, there are easily discernible clusters of people who are more concerned than the average. They include *Involved Canadians*, older people, and those who report having heard some of the recent debate about biotechnology. The following graph shows the various demographic subgroups and the percentage of Canadians within each subgroup who report a negative reaction to biotechnology.

Concession and statistics	Nega	tive Reaction to		
Total	14	Total	14	
volved	18	Heard about recently	17	
en Pop	12	Not heard about recently	11	
<35	9	Univ	14	
35-54	14	College	10	
30-54 55+	20	HS or less	17	
		65k+	12	
tlantic	12	35-65k	12	
uebec	11	<35k	16	
Ontario	16			
rairies	12	Male	13	
Number of States and States		Female	15	

Awareness of biotechnology-related issues has risen dramatically between surveys. There can be little doubt that the substantially increased volume of media coverage over the past few months has brought the issue to more significant levels of public awareness and recognition. There is a remarkable 15% increase in the number of people who say they have heard about stories or issues involving biotechnology over the past three months. That brings to a majority the number of people saying that, and a significantly higher proportion of *Involved Canadians*.





Nevertheless, heightened awareness has not translated into much deeper familiarity or expressed interest. Those levels – quite low in October – have barely shifted in February. The reasons for that, at least according to focus group participants, involve a mix of factors. Some find the issues quite complex and esoteric, a debate about a branch of science that they find hard to follow. Others find it hard to directly link benefits, or risks, to what they know of the actual practice of genetic modification. And many believe the issue has become politicized, somewhat inappropriately, and have lost interest in the rhetoric and conflict. As a result, only an extremely consistent 5-6% of the population is willing to claim that they are very familiar with biotechnology.

POLIARA AND EARNISCLIFFE		Familiarit	ty with E	Biotec	ahno.
2000 Survey	6	50	29		15
- I999 Survey	5	48	33		14
998 Survey ¹	6	39	33	22	2
- c		20 40 ■ Very familiar □ Not very familiar	60 □Somewh □Not at all		100 1

¹Environics Research Group, *Renewal of the Canadian Biotechnology Strategy: Public Opinion* Research (1998). The Executive Summary of this report is available at: http://strategis.ic.gc.ca/cbs.

The proportion of the general population expressing a high level of interest in biotechnology is comparatively low as well and hasn't increased despite the months of intense media coverage. Where it has moved somewhat more significantly is among *Involved Canadians*, where interest was somewhat higher to start with. Almost one quarter of these people now say they are very interested in the subject.

		Total S	ample		
ebruary 15		49		25	10
October 14		49		28	9
0	20 ■Very	40 ⊡Somewhat	60 □Notvery	80 □Notat	100 all
		Involved C	anadians		
ebruary	23	49		21	6
October 1	9	52	and the second second	25	4

As further evidence of the apparent lack of interest in biotechnology, three of five Canadians say they have never talked about biotechnology with anyone. That number has changed only slightly from the fall.



Assessments of Benefits and Drawbacks

On the whole, most people continue to see substantially more benefits than drawbacks to biotechnology, though the gap has narrowed since October, quite substantially in several key areas like health and food quality. In many ways, this overall positive assessment expresses the biotechnology conundrum quite well. As a general proposition, biotechnology is greeted neutrally to positively, with an underlying assessment that it promises more benefits than drawbacks. However, once the question becomes much more specific – e.g., the assessment of actual applications of the technology – attitudes begin to polarize as people begin to assess each on a case-by-case basis. Focus group discussions show clearly that

POLLARA AND EARNSCLIFFE

most people want to use a case-by-case frame for their own decision making, because they want to apply a risk-to-benefit equation to test the potential marginal personal benefit for themselves of each application.

The following graph shows the assessed benefits and drawbacks along nine variables. The availability of food and health care applications seem to many to promise the largest benefits. The potential moral and ethical conundrums pose the largest drawbacks.

	ana atau kata panana kata kata kata kata kata kata kata		Ornal Classic Court Hospital Classic Classic Classic Court of the Cour	
Amount of food	36	34	11 8	
Health - future	35	30	12 11	
Health - today	31	29	13 12	
Economy - today	27	42	11 7	
Economy - future	27	41	12 7	
Environment - future	26	38	13 12	
Environment - today	25	35	17 11	
Quality of food	24	36	15 15	
Moral and ethical values	12 2	8 26	16	

The following graphs show the degree of change in perceptions since the fall. The erosion in the number of Canadians saying they expect major benefits has been quite significant. Similarly, the increase in those seeing major or modest drawbacks has been quite consistent.

	October 1999	February 2000	Net
Amount of food	44	36	Down 8
Health - future	42	35	Down 7
Quality of food	38	24	Down 1
Environment - future	36.	26	Down 1
Health - today	35	31	Down 4
Economy - future	34	27	Down 8
Environment - today	26	25	Down 1
Economy - today	24	27	Up 3
control grants and the second			
oral and ethical values	14 20 40 50 80 1 ■ Major benefits	00 0 20 40 60 80 Major benefits	100
POLLARA AND EARNSCHIFE Hummannerwanner	20 40 60 80 1 ■ Major benefits	00 0 20 40 60 80 Major benefits Dra	wback
POILARA	20 40 60 80 1 ■ Major benefits	00 0 20 40 60 80 Major benefits	100
POLIARA EARISZIFFE HUMMMANTERMONT	20 40 60 80 1 ■ Major benefits	00 0 20 40 60 80 Major benefits Dra	100 Wback
POLLARA AND EARISCIFFE Manual Million and Million	20 40 50 80 1 Major benefits	00 0 20 40 60 80 Major benefits Dra February 2000	100 Wback
POLLARA EARISSLIFFE DECOMPOSITION DOCTOBER Amount of food	20 40 50 80 1 Major benefits 19999	00 0 20 40 60 80 Major benefits Dra February 2000	100 Net Up 6
POLLARA AND EANISCIFFE Manual Annual Annual Annual Annual of food Health - future 10	20 40 50 80 1 Major benefits 19999	00 0 20 40 60 80 Major benefits Dra February 2000	100 Wback Net Up 6 Up 3
POLLARA EARISELIFFE Manual M	20 40 50 80 1 Major benefits 19999 10	00 0 20 40 60 80 Major benefits Dra February 2000	100 Net Up 6 Up 3 Up 9
O C C C C C C C C C C C C C	20 40 50 80 1 Major benefits 19999 10 10 10 10 10 10	00 0 20 40 60 80 Major benefits Dra February 2000	100 Wback Net Up 6 Up 3 Up 9 Up 3
Control of food Mealth - future Environment - future Health - today Economy - future	20 40 50 80 1 Major benefits 19999 10 10 10 10 10 10	00 0 20 40 60 80 Major benefits Dra February 2000	100 NWDACK Net Up 6 Up 3 Up 9 Up 3 Up 8
O Control of the second secon	20 40 50 80 1 Major benefits 19999 0 10 10 0 8	00 0 20 40 60 80 Major benefits Dra February 2000 11 8 12 11 15 15 13 12 13 12 12 7	100 Wback Net Up 6 Up 3 Up 9 Up 3 Up 8 Up 5



POLLARA

The Question of Risk

As indicated just above, the question of risk is central to attitudes about biotechnology and its applications. Most people understand that many things in life carry risk and they tend to believe that you can't move forward without taking some risk. Biotechnology is no exception to that and Canadians generally do not impose a zero-risk frame on the technology. Nevertheless, they believe there are risks particular to biotechnology and, as a result, they tend to employ a personal sense of the risk/benefit ratio to decide whether, on balance, a particular application is worth proceeding with in spite of the risk involved. The larger the perceived benefit – for example, health benefits are highly prized – the larger the willingness to take risk. There is a clear logic chain. Most people believe that not enough will ever be known about the safety of biotechnology. It seems to follow then that almost two-thirds of Canadians agree that "we have to accept some risk to achieve health benefits from biotechnology research." However, in what is a commonsense approach, most Canadians very much want further research into the risks of biotechnology so that they can understand the long-term implications.



19





There clearly is some mixed emotion about all this. Though in the previous response Canadians were willing to accept some risk, they increasingly are not sure that enough is known about the safety of products made through biotechnology to allow them to be used. Again, the generic question generates one kind of response, the specific trade-off question, another.



Ultimately, when people are given a bit of middle ground - i.e., that government should *slow* the use of biotechnology until more is known about the risks - they agree in increasingly larger numbers.



The Role of Government

Over the past few months, performance ratings of the federal government in relation to biotechnology have eroded slightly, both on its overall performance as well as its work on specific issues. The number of Canadians who say the government is doing a poor job has grown by three percentage points among the general population, and higher among *Involved Canadians*.

It is fair to say that the ratings probably reflect more the rise in concern about biotechnology than a precise knowledge of what government does in the area. In fact, focus groups show that people have trouble identifying the various government roles. For instance, Canadians know very little about current regulations or the workings of the regulatory system. Few describe themselves as familiar with the system and most seem willing to assume the best, that someone's in charge and doing the proper job. When it comes to food, the overwhelming majority believes that food on grocery shelves is safe and that it has been tested for safety.



POLLARA AND EARNSCLIFFE

Ultimately, they want government to carry out two roles quite vigorously. They want it to facilitate the technology in order to gain the benefits they think important but they also want aggressive regulation and intensive research so that the risks can be managed and minimized.

Clearly, the demand for aggressive regulation is based almost entirely on the perceived long-term risk, and not on any criticism of the current regulatory system. In fact, virtually no Canadian, including *Involved Canadians*, is willing to say that they are very familiar with the regulatory system.







By a margin of about three to two, Canadians reject the proposition that too much regulation will render the sector less successful.

Though concern is rising about some aspects of biotechnology and fuelling demand for increased regulation, perhaps counter-intuitively it is not apprehension about food safety that is driving that increase. In fact, the current debate seems to have convinced more Canadians about the safety of their food. In February, more people felt strongly that their food was safe and had been tested for safety by government.

POLLARA AND EARNSCLIFFE







Comparing data from the three years' worth of Canadian Biotechnology Strategy polling shows a steady increase in the number of people dissatisfied with government performance on biotechnology. However, the much larger number of people who are still willing to say government has done a fair job or better is further evidence that there is an overall comfort level with biotechnology.

	7					
2000 Survey	2	17	46		29	6
1999 Survey	2	18	47		26	6
1998 Survey (Environics)	4	24	4:		12	16
	0	20	40	60	80	

However, *Involved Canadians* – the people who show much higher levels of knowledge and familiarity with biotechnology – also show higher levels of dissatisfaction with government performance.

Fotal sample	2 17	46	29	6
Involved Canadians	16	43	36	

The declines in positive rating for government performance are reflected consistently throughout the list of specific biotechnology issues. Comparing the data from the fall and winter shows a fairly uniform decline in the number of people volunteering that the government has done a good or excellent job.

POLLARA AND EARNSCLIFFE		Performance
	October 1999	February 2000
Canada benefits from economic opportunities	27	6 22
Canada benefits from new products and processes	26	3 23
Protecting health against risks 4	23	4 18
Ensuring biotech is being used in ethical ways	21	3 16
Protecting environment against risks	19	4 17
Interests of average Canadian are taken into account	16	13
Informing Canadians about role of government	10	2 10
0	10 20 30 40 ■Excellent □Good	50 0 10 20 30 40 50 ■Excellent □Good

POLLA RA AND EARN SCLIFFE

And, as in October 1999, there is a mismatch between what people express as their desired priorities for government and how they perceive the government's performance on those priorities. In the following graph, it is clear that government gets its highest marks for its performance on the two priorities Canadians rank least in importance. Conversely, it receives only middling ratings for the two highest priorities of Canadians – protecting health and environment against risks.



The ambivalence and inner tension felt by Canadians are well illustrated by their apparently contradictory responses to two separate questions in the survey. Majorities believe both that government should encourage the development of biotechnology despite unknown risks and that government should not allow the future use of biotechnology until it conducts further research into long-term health and environmental impacts.



Focus group discussions show that ambivalence quite clearly, and the way people resolve it is to demand of government the dual-track roles of facilitating the benefits while understanding and minimizing the risks.

Decision Making in Biotechnology

POLLARA AND EARNSCLIFFE

There has been little change over the past few months in Canadians' attitudes towards decision making in allowing biotechnology products. They continue to believe strongly that experts should make those decisions and that they should use scientific evidence of safety as their guide. Though the public wants to be informed about those decisions and to have access to studies about risk, it does not want to lead in decision making.



Most people believe that science should be the guide to decision making. They see ethical issues as important but as a secondary driver. In fact, if the "best available evidence" says a product is safe, most people see that as a reasonable standard for approval; that is true even if the standard is "*most* available evidence."



POLLARA AND EARNSCLIFFE

There are mixed views about whether government should simply make the decisions on behalf of consumers or provide information to consumers so they can decide by themselves. In part, the mixed results are a function of a normal and strong desire by people to decide things for themselves, leavened by an acknowledgement that decision making in this area is complex and is better left to experts.



34



Argumentation

POLLARA AND

This survey, as did the last, tested a variety of arguments dealing with biotechnology, pro and con. This exercise helps to clarify underlying drivers of opinion and suggests ways to frame communications messaging. On the whole, the results were quite consistent directionally, though there was a decline in the number of people who found some of the pro arguments very persuasive.

The more important learnings centre around the fact that while most people hold several positive views of biotech, many of them share several negative views as well. It is reasonable to infer that most people harbour a level of internal tension about biotechnology. There is support for development of the technology to gain its benefits mixed with varying degrees of apprehension about its risks. This is clearly evident in the arguments they find most persuasive – pro and con. The most favourable argument is one that promises cures or treatments for illnesses – the most valued potential benefit of biotechnology. The most negative argument is the one that indicates that biotechnology may create long-term risks to health and the environment.

There has been a decline in the number of people who *strongly* share the view expressed by arguments in favour of biotechnology. In each of the four arguments, there has been significant slippage, about half of it going to a slightly less assertively positive view, half of it going to a negative view. To fully understand the context, however, it is important to indicate that fewer than one in five take negative views on *any* argument.

POLLARA AND EARNSCLIFFE


While a majority of people see merit in each of the four arguments, there is no doubt which ones most people find most persuasive. When asked to select the strongest argument, they immediately support the two they believe produce the most important benefits.



As evidence of the internal tension on biotechnology, most people find it possible to agree as well with the arguments posited against biotechnology. That is true of three of the arguments, as shown in the graph below. There is determined resistance to the argument that there should be discomfort with changing what God or nature created.

POLLARA AND EARNSCLIFFE



However, when asked what the strongest argument against biotechnology might be, there was little doubt. As shown in the graph below, people went to the direct argument about risk by a margin of better than two to one over the next argument, which posed another version of the risk scenario.



The weakness of the philosophical argument is further underscored when people are asked directly whether they agree with the proposition that "Scientists have no business meddling with nature." Overwhelmingly, they disagree.

	"Sci	entists hav	ve no busir	ness meddling	g with natu	ire."
February	12	20		45		21
October	9	21		50		18
	0	20	40	60	80	100

GM Food

Finally, the survey re-tested some of the questions asked in the fall of 1999 about genetically modified (GM) foods. Given the current public environment and the complexity of this issue, it is important to understand that these few questions just begin to test the full dimensions of public attitudes towards GM foods. A comprehensive examination of the issue area was beyond the scope of the mandate of the previous survey (which was to establish baseline data along a broad front of biotech issues) and the update in February (which was to test whether the fall data were still reliable).

The focus groups delved much more deeply into GM foods and those results are outlined in the section below.

As indicated earlier in this report, most Canadians believe the food they eat is safe and has been tested. That finding indicates that the current debate about GM food has not affected the view of most people about the safety of the food they eat. However, focus groups indicate that Canadians continue to be surprised at the degree to which GM ingredients are present in their food. Awareness is growing slowly but only 30% of Canadians believe they have consumed GM food in the last month, a statistic that probably belies the reality that anywhere from 60 to 75 percent of all processed foods contain ingredients or come from plants that have been genetically modified.

POLLARA AND EARNSCLIFFE



There are findings in the survey that suggest that the resistance to biotechproduced food is less entrenched and more strategic than might otherwise have been assumed. Though resistance has grown since October, a majority of Canadians (59%) say they would buy biotech-produced food if it were more nutritious than other food. Only a small minority (9%) strongly disagrees. However, as is consistent with the findings elsewhere, as the benefit seems less important, the resistance increases. A majority say they will not buy these foods if the identified advantage is restricted to lower price.

POLLARA AND EARNSCLIFFE





D. THE FOCUS GROUPS - MAIN FINDINGS

Top-of-mind awareness about biotechnology has grown since last fall, but familiarity and interest remain relatively low. Consistent with the quantitative survey results, there has been a notable rise in the number of Canadians that have noticed the subject of biotechnology over the past three months. However, this rise has not translated into engagement. The February focus groups signal no notable change in the level of interest or concern that Canadians had about biotechnology in the groups conducted last October.

While people have heard more in recent months, they are as likely to have heard positive news as negative news. Most focus group participants associate biotechnology with leading-edge health and medical technology. A sizeable minority of participants initially associate biotechnology with the controversy surrounding GM food.

Most people are initially neutral to positive about biotechnology, with a small minority showing relatively entrenched negative opinion. These initial sentiments are usually linked to their primary association. A positive view tends to be tied to awareness of health or medical applications, whereas a negative view tends to be tied to awareness of GM food. After initial discussion, however, it becomes evident that most people carry both positive and negative views toward biotechnology. Many who have not directly confronted the subject previously are torn by the issues involved.

Focus group participants expressed mixed views about biotechnology product applications. Consistent with the fall focus group findings, people clearly differentiate between medical or health research applications and other applications. They feel positively towards and strongly support biotechnology applications that can help cure people or prevent diseases, but show little support for what they consider more 'frivolous' uses such as making vegetables more attractive. Applications that promise environmental benefits (e.g. forestry, toxic cleanups) were generally mixed. In several groups, respondents questioned the impact of these applications on biodiversity, and this had a negative impact on overall support for the application. Participants understood that all biotechnology applications (like most other things) carry risk, and were prepared to accept those risks in cases where the potential benefit outweighed the risks. If the application was thought to produce a substantial health or medical benefit, participants were prepared to accept a higher level of risk.

Participants' acceptance of biotechnology applications was most often based on a risk/benefit analysis, evaluated on a case-by-case basis. This analysis employed a system of measurement that was heavily influenced (positively or negatively) by certain common factors. Respondents tended to be more supportive of applications and products that seem to have the potential to positively affect them personally, and provide a significant health or environmental benefit. Conversely, if the potential benefits were viewed as accruing to a subset of society only, this substantially reduced their value. If the biotechnology application were to entail the manipulation of the genetic structure of higher order organisms, or if the application entailed the insertion of genes across plant/animal/human boundaries, the risk was viewed as being much higher.

With a few exceptions, the majority of participants believe that science should be the primary guide to decision making about biotechnology applications. They do not see biotechnology as an overarching moral or ethical dilemma though they acknowledge it has some of those dimensions. Health and environmental risks are the key drivers. Ultimately, if an application is deemed safe by the "best available" scientific research, most say that their concerns would be reduced. This is not to say that the "best available" scientific evidence would make all biotech products acceptable; rather that science is the most effective means to abate perceived drawbacks. Individuals who tend not to be driven by science tend to be small in number, but also tend to be among the most hardened in their opposition to biotechnology.

The GM food debate has not penetrated very deeply as yet in most of the centres, although Vancouver is an exception. Where it has registered (Vancouver), it is evolving into a significant debate about safety and science. In the other centres, it is viewed largely as a complicated and somewhat ideological conflict led by interest groups.

Most people believe the food on grocery shelves must be safe and has been tested by government. However, there is widespread confusion about the nature of the testing system. Most believe the testing of food involves spot inspection, largely of meat and fresh produce. Few have thought through the testing or inspection of processed foods. There is virtually no understanding or awareness of the actual regulatory system for approval of foods. Indeed, in the context of discussing GM food, participants tended to probe for more information about the food-testing system in Canada and, on the whole, became more concerned as the subject was discussed. Their expectations are that GM food has undergone more rigorous testing than organic food in order for it to have been allowed on store shelves.

Most people advocated an "informed choice" approach to GM foods, and that leads to some form of labelling. Many accept voluntary labelling as a reasonable step but will expect a mandatory system if a voluntary one does not produce results. Involved Canadians are more likely to want a mandatory labelling system. However, some, mostly those who are less engaged, are not sure that level of compulsion is necessary and they are unsure precisely what a label would say or how it would advance their consumer needs.

Most had no idea what government's role is in the area of biotechnology, and once raised, a number of participants became uneasy about what government was doing (or not doing) in this field. As such, the majority felt that the federal government had not performed well on biotechnologyrelated issues, because they had not heard anything about what government had done or the components of the regulatory system. Similar to food inspection, most assumed that some type of regulatory framework was in place. However, many expressed concern that government cutbacks had eroded the effectiveness of the regulatory system.

There was broad support for a two-track government policy approach, including a strong regulatory and scientific oversight system in addition to fostering the development of the industry. Participants had no problem with government playing dual roles, as long as the regulatory system could be insulated from economic pressures.

The first priority for the federal government is a comprehensive regulatory testing system before biotech products get to market, along with long-term study of potential health and environmental impacts. Economic support to industry was deemed important, but much less important than health and safety regulations and research.

Messaging or arguments that focus on health or environmental benefits tended to be much stronger than those that promise to expand the food supply or convey economic benefits to individual producers or the economy as a whole. Indeed, arguments about "solving world hunger" were initially met with tepid support but quickly moved to uncertainty once discussion about the subject took place and questions were raised about whether there is already enough food to feed the world. It should be noted that, as presented, the statements left many participants, especially Involved Canadians, wanting for more specifics.

On the negative side, it is the argumentation about long-term, unknown or unknowable risk that is most effective. There is little support for arguments that changing things God or nature created should mean ending biotechnology efforts. While some people express discomfort with changing the natural order of things, they have become resigned to it on a broad front of activity and believe it part of modern science.

On the whole, negative messaging is stronger than positive messaging. Even in the absence of detail about what the risks are or might be, the negative messages about long-term risks are disconcerting to most. Any communications effort will have to respond directly to those fears.

There is virtually no way to create positive messaging around GM food. There is only the prospect of trying to convince people they are safe or at least benign. Largely, participants don't understand why there are GM ingredients in food, and the linkage to agricultural crops is only hazily understood. It is reasonable to infer that people would prefer, all things being equal, not to have to confront the issue. Functional foods might provide an acceptable rationale over time but as of now there remain questions about what the marginal benefit of these products would be.²

 $^{^{2}}$ A functional food is similar in appearance to, or may be, a conventional food; is consumed as part of a usual diet; and is demonstrated to have physiological benefits and/or reduce the risk of chronic disease beyond basic nutritional functions.

Consistent with results last fall, there is a widespread distrust of a variety of institutions and potential spokespeople on all sides of the debate. There are few voices people would believe to be completely trustworthy in providing information about biotechnology.

POLLARA AND EARNSCLIFFE

- On a government level, there was widespread mistrust of politicians and senior civil servants. In addition, there was concern about the basic competence of government officials to fully understand and manage risk. The only people in government that were deemed to be relatively trustworthy were officials involved in research and/or regulatory processes.
- Business was widely perceived to be in a conflict and would be expected to extol products out of self-interest.
- Scientists in general were regarded with some suspicion because most believed they were too heavily influenced by potential funders of research. Curiously perhaps, participants tended to differentiate between scientists and university academics, whom they felt were the most independent in the scientific community.
- Interest groups continue to be a source of deep suspicion among Canadians. They tend to be regarded as uni-dimensional and, in some cases, radical. People tended to believe that interest groups always represented one side of a debate and were not to be trusted to provide dispassionate or even credible views.

The most trustworthy spokespeople were those identified as having independent status and no obvious benefit to gain. That was the basis of appeal for university academics. Others that fall into that category are doctors and hospital researchers.

Most people were willing to accept the word of expert panels or advisory boards as long as they were clearly at arm's length from government and industry, and had representation from "all sides" of the issue. Participants felt that independent advisory boards (like the Canadian Biotechnology Advisory Committee) carry credibility as information sources on biotech. On many questions, there were substantial differences between participants from the general population and those from the Involved Canadians groups. Though initial attitudes were roughly similar, the Involved had a higher awareness and knowledge base. Starker differences emerged during discussion as participants were exposed to more detail.

The Involved participants tended to become more concerned and to differentiate clearly between acceptable and less acceptable applications. As is consistent with survey results, concern increased as higher life forms were involved and as boundaries were crossed between plants, animals and humans. Their desire for further information sharpened. They also tended to display increased scepticism about the ability of governments and scientists to fully understand and manage the potential risks. Interestingly, heightened concern did not alter their initial assessments of the technology; rather it seemed to make them determined to be more watchful. On the whole, they were attracted to the potential benefits (largely the ones involving health and medicine) and accepted the current risk/benefit equation but were insistent on more research into and understanding of the long-term health impacts.

The general population participants tended to have more difficulty understanding applications and differentiating among them. They tended to be more accepting after detailed discussion and tended to extrapolate their basic position forward without differentiation. However, in many cases, that basic position was one of uncertainty. Many members of the general public find the idea of these sorts of applications unsettling, and that leaves them torn about whether they are acceptable or not. In general, they tended to fall back on a basic assumption that experts in government and scientists would know more than they do and would tend to operate in the public interest. Their level of interest, moderate at best, did not seem to increase substantially. For instance, they, unlike the Involved, displayed little interest in being consulted about biotechnology issues or in participating in events like town halls.



E. CONCLUSIONS

While awareness has grown, the public continues to be disengaged on biotechnology, and in the absence of a catalyzing event are unlikely to become engaged. Current voices of opposition to biotechnology and GM foods have thus far not been sufficiently credible and/or widely enough heard to engage the public.

It seems clear that heightened awareness leads some people, particularly those who are more active and involved, to become more uncertain about biotechnology. After discussion of specific applications, concern rises and determination to seek more information seems to get firmer. In the absence of available information (research studies, etc.) that satisfies these concerns, uncertainty can lead to opposition among this segment of the population.

For others, particularly members of the general public who display little initial awareness and interest, further information on biotechnology is difficult to cope with, and they can become confused by the issues. This segment of the population tends to believe the issue is quite complicated, an argument between competing factions and, as a result, a debate they are not sure is worth following closely. These people are more likely to rely on experts (including advisory bodies to government) to represent them.

There are some applications that are clearly a step too far for a majority of participants. Applications that provide potential health or environmental benefits, and are of benefit to all, are most likely to be acceptable. Applications which are deemed to be cosmetic or are not seen as fulfilling a societal need tend to be met with resistance. As the issues begin to involve higher and higher life forms or more and more crossing of plant, animal and human boundaries, many begin to dig in and their opposition becomes quite determined. They can only be swayed by the clearest of potential medical benefits.

As awareness grows, people tend to reject a comprehensive view of biotechnology. Rather, they seek to segment applications (or categories of applications) and evaluate the marginal benefits of each on a case-by-case basis. This case-by-case evaluation approach leads to the rejection of broadly stated messages about biotechnology. It also reflects the fact people tend to possess a discrete conception of the acceptability of individual applications, and as such, views toward one application tend not to influence views toward another.

Participants understand and accept that risk management is a fact of life, though they still tend to be risk averse. Some are resigned to the fact that their food supply may contain GM ingredients, although a majority questions whether the benefits of these foods outweigh their potential risks. They are uncomfortable about much of this but presume that someone's in charge and that somewhere the appropriate decisions are being made. It will be difficult to shake this general posture because they aren't sure whom to trust in any debate about these issues and do not see tangible potential benefits. By and large, most people see biotechnology as a technical scientific issue to be resolved on those grounds.

It was clear in the focus groups that the way ahead for government includes a visible two-track process – most want to reap the significant benefits of biotechnology but only within a rigorous framework of strong regulatory oversight and determined, directed research to settle the longterm health and safety issues. While participants were content with government playing multiple roles, they did not want one-sided information. They reject any notion of an advocacy effort by government. They want government to present information about biotech in as neutral a form as possible, including both risks and benefits. Government credibility rests on its ability to be seen as a player that can realize the benefits of biotech but is prepared to reject any applications that threaten the health or safety of Canadians.

People are divided when asked whether government should slow the use of biotechnology until more is known about the risks, or whether we have to accept some risk. Mostly, they feel they don't have enough information to make that decision. They tend towards the latter, however. They suggest going forward with health-related applications and slowing down with cloning and food.

GM food is generally viewed as the least beneficial aspect of biotechnology, and is therefore the most likely launching point for opposition.

51



F. APPENDIX

- 1. Moderator's Guide
- 2. Questionnaire



Moderator's Guide

Probing on general level impressions

When you hear the word biotechnology, what are the first thoughts which come to mind right away? Please write them down on a piece of paper.

Overall, do you have a positive reaction or a negative reaction to the term **biotechnology**? Please tell us what you wrote down, and where you developed these impressions.

Over the past couple of months, would you say you have heard more, less, or no more or less than in previous months? Do you think that this will subside or that you will be hearing more and more in the future? Thinking about what you have been hearing lately, is it more and more positive, or more and more negative about the impact and potential impact of biotechnology?

Have your views changed over the past year or two on this subject, and why?

 Biotechnology has applications in a number of fields. Please write down examples of biotechnology-related products or applications that you have heard about.

Definition: Biotechnology applies science and engineering to living things like plants and animals to create new products and processes. It includes numerous applications, everything from cross-breeding plants to genetic testing to screen for inherited diseases.

- Are you interested in this subject? Why does it interest you? Those of you who feel that it is not interesting, can you talk about why it is not all that interesting to you?
- From what you know about biotechnology, in general, do the potential benefits outweigh the potential risks, or vice versa?

Biotechnology as industry

Compared to other countries, does Canada have a substantial biotechnology industry?
 Why or why not? Should we be trying to be leaders, followers, or in the middle of the pack? Why?

Compared to other Canadian industries, would you say that biotechnology is very important, moderately important, or not very important to the **future** of the Canadian economy? Why do you say that?



and

720->

COMMUNICATIONS TESTING

What have you heard about aspects of biotechnology, and from what source? Do you hear-10% more about this from government, from the industry, or from interest groups? Is what you hear more negative than positive or more positive than negative? –/Od

10a

106

na

When it comes to learning about the potential benefits of biotechnology, who are you more likely to trust to have the most reliable information? Probe biotech industry, federal information government, provincial government, ENGOs, university researchers. In addition, do you trust them to give it to you in an honest and clear fashion?

How about when it comes to the potential drawbacks associated with biotechnology?

I'm going to read a series of arguments that people make when they advocate biotechnology. Thinking about each of the following arguments, which resonate with you? Probe: Which stakeholders of those listed above would you be most anxious to hear from, and most likely to trust? (In each case, a specific probe will be made of the role of the federal government, if it is not explicitly raised by the participants.)

Biotechnology has the potential to help solve world hunger.

Biotechnology has the potential to help solve serious environmental problems.

Biotechnology has the potential to help cure or treat serious illnesses.

Biotechnology has the potential to strengthen our economy and improve our standard of living.

 Biotechnology is one of the modern technologies that will drive the future economy of the world.

I'm going to read a series of arguments that people make when they outline the drawbacks of biotechnology. Thinking about each of the following arguments, which resonate with you?

- Biotechnology involves changing things that God or nature created, and that makes me uncomfortable.
- I Biotechnology may be creating unknown, long-term risks to health or the environment.
- Biotechnology involves experiments which could go wrong and cause serious harm.
- Biotechnology can lead to ethical decisions which are troubling and impossible to resolve to everyone's satisfaction.

With respect to the preceding issues, imagine that you wanted to get information about them. Where would you like to get it, in what form, and from what stakeholders? What would be the most effective way of getting it to you?



23056 How likely would you be to consume information from the federal government if it were delivered in the following ways:

23 ^Q ■ At a special biotechnology web site, which was advertised and promoted.

73 Via e-mail to all those who indicated they wanted regular updates.

- 23 C
 Through newspaper and magazine advertisements or inserts.
- Through a documentary video which was available to everyone who wanted a copy for a dollar or two.
- 238 -
 - Through a publication or a brochure which you could send away for.
 - Through an extended five-minute televised segment, bought as advertising.
 - How much and in what ways should the government attempt to involve people like you in decisions about biotechnology policy?

Would you be interested in participating in a consultative process like a town-hall meeting on biotechnology?

Would you be interested in attending a two-day conference to explore biotechnology issues in detail with a group of other Canadians?

BIOTECHNOLOGY APPLICATIONS

People seem to be more comfortable with some applications of biotechnology than with others. For each of the following, please tell me if you feel positively or negatively of 070 toward them. In each case, tell me if you feel that there are no or few risks, or if you think that the benefits outweigh whatever risks there may be.

7.70-70

Implanting plant genes in other plants (like corn that has a gene from another plant inserted into it to resist certain kinds of insects) to help improve the quality and quantity of food.

Using genes from one organism to change another organism in order to help clean up environmental problems.

 Changing the genetic makeup of trees to make them resistant to diseases and insect attack.



Creating a potato that insects will not eat or destroy.

Modifying genes in a human embryo to eliminate an inherited disease.

Creating genetically modified fish that will be healthier and more disease resistant.



Breeding genetically engineered livestock animals to have less fat.

340-20

Implanting animal genes in plants to help improve the nutritional value or appearance of food products.

Breeding genetically engineered animals for use in medical research.

Let's try to clear up what elements are more likely to create acceptance or rejection. I would also like to know whether your views on the applications should be interpreted as hard directions to government, or impressions which you would like taken into account. Are there any exceptions to that?

RISK MEASUREMENT AND MANAGEMENT

As mentioned earlier, the field of biotechnology raises issues of risk and benefit to society. I'm going to ask a few questions that attempt to get at how you feel about what the risks and benefits are, and how you think decision makers should approach decisions regarding biotechnology.

37

From what you know now about biotechnology, do the potential benefits outweigh the potential risks, or vice versa?

 Some people are confident that enough is being done to study and monitor the risks associated with biotechnology. Others are worried that not enough priority is being attached to this. Which of these points of view is closest to your own? Why? 3%

Some people say until more is known about the risks, governments should slow the use of biotechnology. Others say we have to accept some risk to achieve health benefits from biotechnology research. What do you think is the best approach? Please explain your point of view? 39

If most scientific evidence says that a particular use of biotechnology is safe and should 40 be allowed, should that be the approach we use? OR should we use a precautionary principle, where we ban a product if there is any potential of future risk (knowing that no one can rule out the risk of virtually anything). Why?

Should scientists be the primary decision-makers about biotechnology, or should it be ordinary Canadians, or some combination of the two?



GM FOODS

From what you know, is all the food that gets to the grocery store tested for safety? How, when, by whom?

- If you had to guess, what percentage of the processed food we eat on a daily basis do you think is genetically modified or comes from plants that have been genetically modified?
 - The amount is anywhere between 60% and 75%. What impact does that have on your views of genetically modified foods?
- Do you feel that the authorities are doing enough to ensure your safety when it comes to GM foods? What would reassure you?
- Is having GM food a good thing, a bad thing, or not much of an issue to you at all?
- What do you need to know about the GM aspects of food that you buy at a grocery store?
 How would you feel about the following approach? (test likely scenarios)
 - Government communications campaign 47b
 Slem b ->e
 - Information at the grocery store 4nc
 - Voluntary labelling 47d
 - Mandatory labelling47e

12

50070

FINAL QUESTIONS

0

I'd like to go back for a minute to the beginning of this discussion.

Do you think that your views on biotechnology could change, and if so, what would make them change? Are there some people or organizations who would be more likely to cause a change in your opinions?

IF TIME PERMITS Most new inventions are protected by what are called patents. Patents ensure that inventors are rewarded by making sure that their inventions cannot be copied for a period of time. However, it also means that until the patent expires, the inventor controls the availability and price of the invention.

57

Some people feel that the idea of patent protection is necessary in the field of biotechnology, because we need to encourage inventions in this area for all the benefits which they can bring. Others are uncomfortable with the idea of patents in the field of biotechnology, because there is something wrong with the idea of patenting a life form such as an animal or a plant. Which of these two points of view is closer to your own? Let's discuss your views.



ab

Questionnaire

PERCENT PERCENT

¹. When you hear the word **biology**, do you have a positive reaction, a neutral reaction, or a negative reaction?

Positive	10	February 2000
Neutral		
Negative		6
DK/NR		2

1b. When you hear the word **technology**, do you have a positive reaction, a neutral reaction, or a negative reaction?

	October 1999	February 2000
Positive		65
Neutral		
Negative		5
DK/NR		2

2. When you hear the word **biotechnology**, do you have a positive reaction, a neutral reaction, or a negative reaction?

	October 1999	February 2000
Positive		
Neutral		
Negative		14
DK/NR		4

3. Over the last three months, have you heard anything about stories or issues involving biotechnology?

	October 1999	February 2000
Yes		
No	59	
DK/NR		2

Sa (Bi

Biotechnology applies science to living things such as plants and animals in order to develop dyn, new products and processes.



		February 2000
Very familiar		6
Somewhat familiar		
Not very familiar		
Not at all familiar		
DK/NR	0	0

 Is biotechnology a subject you are very interested in, fairly interested in, not too interested in, or not at all interested in?

	February 2000
Very interested in	
Fairly interested in	
Not too interested in	 25
Not at all interested in	
DK/NR	 1

In your opinion, does biotechnology bring major benefits, modest benefits, modest drawbacks, or major drawbacks in each of the following areas. How about: (ROTATE)

• • •

1000

0000

7. The health of Canadians today

EARNSCLIFFE RESEARCH & COMMUNICATIONS

	October 1999	February 2000
Major benefits		
Modest benefits		
Modest drawbacks	10	
Major drawbacks		
DK/NR		

8. The health of Canadians over the longer term

Major benefits		February 2000 35
Modest benefits		
Modest drawbacks	10	12
Major drawbacks		
DK/NR	10	

9. Canada's economy today

	October 1999	February 2000
Major benefits		
Modest benefits	49	
Modest drawbacks	10	
Major drawbacks		7
DK/NR		



10. Canada's economy over the long term

		February 2000
Major benefits		
Modest benefits	40	
Modest drawbacks		
Major drawbacks		7
DK/NR		

. .

1000

11. The amount of food we produce

	October 1999	February 2000
Major benefits	44	
Modest benefits		
Modest drawbacks		
Major drawbacks		8
DK/NR		

12. The quality of food we produce

X		February 2000
Major benefits		
Modest benefits		
Modest drawbacks	11	
Major drawbacks		
DK/NR		

13. Canada's environment today

	February 2000
Major benefits	
Modest benefits	
Modest drawbacks	
Major drawbacks	
DK/NR	 12

14. Canada's environment over the long term

	October 1999	February 2000
Major benefits		
Modest benefits		
Modest drawbacks	12	
Major drawbacks		
DK/NR		

15. Moral and ethical values

	October 1999	February 2000
Major benefits		
Modest benefits		
Modest drawbacks		
Major drawbacks		
DK/NR		

END OF ROTATION



In each of the following areas, would you say that the federal government is doing an excellent, good, fair or a poor job. How about (ROTATE)

16. Ensuring that the interests of the average Canadian are taken into account as policies are developed for the use of biotechnology.

	October 1999	February 2000
Excellent		1
Good		
Fair		
Poor		
DK/NR		8

17. Ensuring that Canada benefits from the economic opportunities which biotechnology offers.

1	October 1999	February 2000
Excellent		6
Good		
Fair		
Poor		
DK/NR	11	11

18. Ensuring that the health of Canadians is protected against risks associated with biotechnology. October 1999 February 2000

Excellent		4
Good		
Fair		
Poor		
DK/NR	7	8

19. Ensuring that the environment in Canada is protected against risks associated with biotechnology. October 1999 February 2000

	OCIODEI 1999	rebluary 200
Excellent		4
Good		17
Fair		40
Poor		
DK/NR		9

20. Ensuring that Canada benefits from the new products and processes which biotechnology offers.

	October 1999	February 2000
Excellent		3
Good		23
Fair		
Poor		
DK/NR	10	10

21. Ensuring that Canadians are informed about the role of government in biotechnology.

	October 1999	February 2000
Excellent		2
Good	10	
Fair		
Poor		
DK/NR		5



22. Ensuring that biotechnology is being used in ethical ways.

	October 1999	February 2000
Excellent		3
Good		
Fair	41	
Poor		27
DK/NR	11	13

23. Overall, do you think the federal government is doing an excellent, good, fair or a poor job of handling its responsibilities in the area of biotechnology?

Event	October 1999	February 2000
Excellent		Z 17
Fair		46
Poor		
DK/NR		6

How much priority do you feel the federal government should attach to each of the following roles...the highest priority, high priority, moderate priority or low priority? (ROTATE)

24. Ensuring that the interests of the average Canadian are taken into account as policies are developed for the use of biotechnology.

		February 2000
Highest priority		
High priority	42	45
Moderate priority		17
Low priority		5
DK/NR		3

25. Ensuring that Canada benefits from the economic opportunities which biotechnology offers.

	October 1999	February 2000
Highest priority		
High priority	44	
Moderate priority		
Low priority		6
DK/NR		3

26. Ensuring that the health of Canadians is protected against risks associated with biotechnology. October 1999 February 2000

Highest priority	 47
High priority	
Moderate priority	 10
Low priority	
DK/NR	2



27. Ensuring that the environment in Canada is protected against risks associated with biotechnology.

	October 1999	February 2000
Highest priority		
High priority	40	
Moderate priority		13
Low priority		
DK/NR		-

28. Ensuring that Canada benefits from the new products and processes which biotechnology offers.

	October 1999	February 2000
Highest priority		20
High priority	47	
Moderate priority		
Low priority		
DK/NR		3

29. Ensuring that Canadians are informed about the role of government in biotechnology.

	October 1999	February 2000
Highest priority		
High priority		
Moderate priority		
Low priority		
DK/NR		

30. Ensuring that biotechnology is being used in ethical ways.

	October 1999	February 2000
Highest priority		
High priority		
Moderate priority		
Low priority		4
DK/NR		2

END OF ROTATION

31. Would you say you are very familiar, somewhat familiar, not very familiar, or not at all familiar with ways in which biotechnology is regulated in Canada?

Very familiar	 February 2000
Somewhat familiar	
Not very familiar	
Not at all familiar	
DK/NR	 1

I would like to read you some statements which various people have made who are comfortable with the development of biotechnology. In each case, please tell me if you strongly share this view, share it somewhat, or don't share this view. The first one is: (ROTATE)



	October 1999	February 2000
Strongly share view		
Share it somewhat		
Don't share this view		
DK/NR		

33. Biotechnology has the potential to help solve serious environmental problems.

	October 1999	February 2000
Strongly share view		
Share it somewhat		
Don't share this view		
DK/NR		5
The second s		

34. Biotechnology has the potential to help cure or treat serious illnesses.

		February 2000
Strongly share view	52	
Share it somewhat		
Don't share this view		
DK/NR		

35. Biotechnology has the potential to strengthen our economy and improve our standard of living.

	October 1999	February 2000
Strongly share view		
Share it somewhat	53	
Don't share this view	12	
DK/NR		3

END OF ROTATION

36. Which of the statements above is the *strongest* argument in favour of the development of biotechnology?

0.1.1. 1000	F I 0000
October 1999	February 2000
	6
	October 1999 25 16 37 15 6

Now, I would like to read you some statements which various people have made who are uncomfortable with the development of biotechnology. In each case, please tell me if you strongly share this view, share it somewhat, or don't share this view. The first one is (ROTATE)

37. Biotechnology involves changing things which God or nature created, and that makes me uncomfortable.

	February 2000
Strongly share view	
Share it somewhat	
Don't share this view	
DK/NR	

65

6



 38. Biotechnology may be creating unknown, long-term risks to health or the environment.
 October 1999
 February 2000

 Strongly share view
 32
 37

 Share it somewhat
 47
 45

 Don't share this view
 18
 14

 DK/NR
 3
 3

39. Biotechnology involves experiments which could go wrong and cause serious harm.

	February 2000
Strongly share view	
Share it somewhat	
Don't share this view	
DK/NR	

40. Biotechnology can lead to ethical decisions which are troubling and impossible to resolve to everyone's satisfaction.

	October 1999	February 2000
Strongly share view		
Share it somewhat	45	
Don't share this view		
DK/NR		2

END OF ROTATION

41. In your opinion, which of these is the *strongest* argument *against* the development of biotechnology?

October 1999	February 2000
15	
	20
	5

42. Which of the following views is closest to your own? (ROTATE)

	October 1999	February 2000
Decisions about biotechnology should be based mainly on the views and advice of experts about the risks and benefits.		
Decisions about biotechnology should be based primarily on the average Canadian's views of risks and benefits		
DK/NR		7



43. And which of these two views is closest to your ow	vn? (ROTATE)		
	October 1999	February 2000	
Decisions about biotechnology should be based mainly on the moral and ethical issues involved			
Decisions about biotechnology should be based mainly on the scientific evidence of risk and benefit		65	
DK/NR		5	

Please tell me whether you strongly agree, agree, disagree or strongly disagree with each of the following statements which have to do with the role of government. (ROTATE)

44. Government should try not to regulate the biotechnology sector too much; otherwise, it will be less successful.

Strongly agree	February 2000
Agree	
Disagree	
Strongly disagree	
DK/NR	 2

45. Government should regulate the biotechnology sector more than other sectors, because of its unique nature.

Strongly agree	February 2000
Agree	
Disagree	
Strongly disagree	 5
DK/NR	2

46. Government should inform people about biotechnology, and let them decide for themselves whether they want to use biotech products.

	October 1999	February 2000
Strongly agree		
Agree		
Disagree		esseesses and the
Strongly disagree		
DK/NR		2

47. Government should use its expertise to make decisions about which products should be available, on behalf of consumers.

	February 2000
Strongly agree	 23
Agree	
Disagree	 20
Strongly disagree	
DK/NR	 3

67



	October 1999	February 2000
Strongly agree	11	
Agree		
Disagree		
Strongly disagree		
DK/NR		

END OF ROTATION

EARNSCLIFFE RESEARCH & COMMUNICATIONS

Please tell me whether you strongly agree, agree, disagree or strongly disagree with each of the following statements about biotechnology. (ROTATE)

49. I'd like to see Canada lead the world in the development of biotechnology.

	October 1999	February 2000
Strongly agree		23
Agree		
Disagree		
Strongly disagree		7
DK/NR		4

50. Scientists have no business meddling with nature

	October 1999	February 2000
Strongly agree		
Agree		20
Disagree		
Strongly disagree		
DK/NR		

51. The government should conduct further research into the long-term health and environmental impacts of biotechnology.

Strongly agree		February 2000
Agree		
Disagree		
Strongly disagree		1
DK/NR	1	1

52. The government should conduct further research into the long-term health and environmental impacts of biotechnology before allowing any further use of biotechnology.

Strongly agree	October 1999	February 2000
Agree		
Disagree Strongly disagree		10 3
DK/NR		1



 53. When I see a product on a store shelf, I assume that it Strongly agree. Disagree. Strongly disagree. DK/NR 54. When I see a product on a store shelf, I assume that government. Strongly agree. Disagree. Disagree. Disagree. Disagree. Disagree. Disagree. Disagree. Disagree. Disagree. Strongly disagree. Disagree. Disagree. Strongly disagree. Disagree. Strongly disagree. DK/NR 55. I would buy biotech-produced food if it were more nutritistic strongly agree. 	October 1999 	
Agree	18	
Agree	51	
Disagree Strongly disagree DK/NR 54. When I see a product on a store shelf, I assume that government. Strongly agree Agree Disagree Strongly disagree DK/NR 55. I would buy biotech-produced food if it were more nutrit	24 5 1 t it must have bee October 1999 24 49 21 5 1	
Strongly disagree DK/NR 54. When I see a product on a store shelf, I assume that government. Strongly agree Agree Disagree. Strongly disagree. DK/NR 55. I would buy biotech-produced food if it were more nutrit	5 1 t it must have bee October 1999 24 49 21 5 1	7
 DK/NR 54. When I see a product on a store shelf, I assume that government. Strongly agree Agree Disagree Strongly disagree DK/NR 55. I would buy biotech-produced food if it were more nutrition 	1 t it must have bee October 1999 	
 54. When I see a product on a store shelf, I assume that government. Strongly agree	t it must have bee October 1999 	en tested for safety by th February 2000
government. Strongly agree Agree Disagree Strongly disagree DK/NR DK/NR	October 1999 24 49 21 5 1	February 2000
Agree Disagree Strongly disagree DK/NR 55. I would buy biotech-produced food if it were more nutrit		
Agree Disagree Strongly disagree DK/NR 55. I would buy biotech-produced food if it were more nutrit		45 14 7
Disagree Strongly disagree DK/NR 55. I would buy biotech-produced food if it were more nutrit		14 7
Disagree Strongly disagree DK/NR 55. I would buy biotech-produced food if it were more nutrit		14 7
Strongly disagree DK/NR 55. I would buy biotech-produced food if it were more nutrit	5 	7
DK/NR		
	tions than other for	
		ad
Strongly agree		February 2000
Agree		
Disagree		
Strongly disagree		
DK/NR		
56. I would buy biotech-produced food if it cost less than of	ther food.	
Strongly agree	10	February 2000
Agree		
Disagree		
Strongly disagree		
DK/NR		4
 Enough is known about the safety of products made used. 		
		February 2000
Strongly agree		
Agree		
Disagree		
Strongly disagree		
DK/NR		
58. Not enough will ever be known about the safety of biote	October 1999	February 2000
Agree		
Disagree		
Strongly disagree		
DK/NR		3



60. We have to accept some risk to achieve health benefits from biotechnology research.

	October 1999	February 2000
Strongly agree	10	
Agree		
Disagree		
Strongly disagree		
DK/NR		

61. If most scientific evidence says that a particular use of biotechnology is safe, it should be allowed.

	October 1999	February 2000
Strongly agree	12	
Agree		
Disagree		
Strongly disagree		
DK/NR		

62. If the best available scientific evidence says that a particular use of biotechnology is safe, it should be allowed.

be allowed.		
	October 1999	February 2000
Strongly agree		
Agree		
Disagree		
Strongly disagree		2
DK/NR		

END OF ROTATION

EARNSCLIFFE RESEARCH & COMMUNICATIONS

63. Some people are confident that enough is being done to study and monitor the risks associated with biotechnology. Others are worried that not enough priority is being attached to this. Which of these points of view is closest to your own?

		February 2000
Enough being done to study/monitor risks		
Not enough priority attached to it		73
DK/NR	5	5

64. To the best of your knowledge, in the last month have you eaten any food products which have been genetically modified?

Yes	
No. 57 48	
DK/NR	